Industry leading survey of Venture Capital (VC) life sciences investors of funds managing c.$300bn

VCs favouring new investments over existing portfolio and have money to deploy M&A expected to be strong Top investor requirements – Team, Science and Differentiation   London, UK, 11 December 2024: Optimum Strategic Communications (‘Optimum’), the international strategic life sciences communications firm, today announces the results of its Optimum European Life Sciences Investor Survey 2025: […]

Optimum’s European Life Sciences Investor Survey 2025

Weekly round-up: Renée Aguiar-Lucander, Calliditas Therapeutics’ former CEO, scoops Executive of the Year Scrip Award

Congratulations to Renée Aguiar-Lucander, who won the prestigious Executive of the Year Award – Commercial Stage Companies at the Scrip Awards 2024 As the awards celebrated their 20th anniversary, Renée came top from a list of finalists representing the very best in the biotech industry. Renée led the company through clinical development of Tarpeyo (budesonide), […]

Optimum’s hot topic: Can we ‘bottle’ the remarkable biology of people who, against all odds, beat killer diseases?

By Stephen Adams, Optimum Strategic Communications   Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark.  But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases?  What if we could […]

Optimum’s hot topic: “Chrishaps” are scientifically proven hazards – but we don’t have to be Scrooge to avoid them

By Richard Staines Ebeneezer Scrooge, perhaps Charles Dickens’ most famous character, is thought of as one of literature’s greatest villains because of his hatred for Christmas.  This most notorious of misers might have taken things a little too far, but maybe there is something we can learn from him as we approach the festive season […]